Under construction – not a live service

Skip to content

Frontlight Research

Institution

University Hospital Augsburg

Augsburg, GermanyWebsite

Also known as: Universitätsklinikum Augsburg

154running trials
44closed trials
0trials confirmed by the site in the last 60 days
–languages not stated

No trial has been confirmed here yet.

Running trials

Not yet recruiting
Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma
NCT07291102· Phase 3· Source
Not yet recruiting
New diagnostic pathway in primary diagnosis of clinically significant prostate cancer adding PSMA-PET to mpMRI
2026-527906-19-00· Phase 2· Source
Not yet recruiting
Post-intervention dual antiplatelet therapy for mild stroke
2026-525681-22-00· Phase 3· Source
Not yet recruiting
Prospective multicenter clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients - NB2015-LR
2024-517295-37-00· Phase 3· Source
Not yet recruiting
PD-1 Blockade Alone Versus in Combination With Chemotherapy as First Line Therapy in Females With Advanced NSCLC & PD-L1 Expression ≥50%
NCT07877584· Phase 3· Source
Not yet recruiting
A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis
NCT07873801· Phase 3· Source
Not yet recruiting
Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients
NCT07004413· Phase 3· Source
Not yet recruiting
AIEOP-BFM ALL 2025 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia
2025-522190-11-01· Phase 3· Source
Not yet recruiting
REtrieval of Transurethrally Resected Intact En-bloc Vesical Tumors Using a Retrieval Device for Bladder Tumors
NCT07762820· Source
Not yet recruiting
NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer
NCT07178730· Phase 3· Source
Recruiting
A study to evaluate the efficacy of oxaliplatin- or gemcitabine-based chemotherapy after allocation by standard criteria or by genetic markers in patients with resected pancreatic carcinoma
NCT05314998· Phase 3· Source
Recruiting
A clinical trial to learn about the long-term safety of FUB523 (zigakibart) in people with immunoglobulin A (IgA) nephropathy who have completed previous zigakibart trials
2024-519638-22-00· Phase 3· Source
Recruiting
Gustabor Phase 2 - Treating Taste Changes During Cancer Therapy: A Randomized Study Evaluating an AI- Based Nutrition Intervention
NCT07649681· Source
Not yet recruiting
GMMG-HD11/DSMM XXI/64007957MMY3010
NCT07671287· Phase 3· Source
Recruiting
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
NCT07555938· Phase 3· Source
Recruiting
Revumenib Treatment in Combination with FLA Chemotherapy in Paediatric Refractory/Relapsed KMT2A-r, NUP98-r or NPM1-mut Acute Myeloid Leukemia (AML)
2025-521390-14-00· Phase 2· Source
Recruiting
Phase I/II combination umbrella trial in progressive/relapsed/refractory pediatric low-grade glioma (pLGG) (EPILOGUE)
2024-516896-34-00· Phase 1/2· Source
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
NCT07577843· Phase 3· Source
Recruiting
Social Prescriptions and Micro-Learning to Improve Care for Cancer Patients and Their Support Persons
NCT07788729· Source
Recruiting
A Phase 3 Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children with Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders
2025-523079-44-00· Phase 3· Source
Recruiting
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
NCT07489495· Phase 3· Source
Recruiting
Improved Management of Patients With Recent-Onset Stable Chest Pain
NCT07476040· Source
Recruiting
Local Tenecteplase ApplicatiOn subsequent to endovasCular Recanalization in Anterior CircuLation Stroke - the LOCAL trial
2024-516544-26-00· Phase 2· Source
Recruiting
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
NCT07361497· Phase 3· Source
Recruiting
Thrombolysis with Tenecteplase for Acute Ischemic Stroke in Patients taking Direct Oral Anticoagulants
2025-521762-99-00· Phase 3· Source
Recruiting
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
NCT07431281· Phase 3· Source
Recruiting
Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD
NCT07441395· Phase 2· Source
Recruiting
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
NCT07222137· Phase 3· Source
Recruiting
Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residual disease.
2024-512503-39-00· Phase 4· Source
Recruiting
Study on chemotherapy and experimental drugs in patients with Philadelphia Chromosome positive and ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia
2025-520982-39-00· Phase 3· Source
Recruiting
A Phase 1 Study of the Safety and Preliminary Efficacy of CTX112 in Adult Subjects With Refractory Autoimmune Disease.
2024-518528-54-00· Phase 1· Source
Recruiting
SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
NCT07187531· Phase 2· Source
Recruiting
Study to Collect Real-world Performance and Safety Data on Penumbra System® in Population With Acute Ischemic Stroke (AIS).
NCT07107022· Source
Recruiting
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NCT07197307· Phase 2· Source
Recruiting
– IKF/AIO-QUINTIS – A Randomized Phase II Trial Evaluating Fruquintinib in Combination with Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer without Active Liver Metastases
2024-519929-38-00· Phase 2· Source
Recruiting
Intervention With Tralokinumab in Patients With Moderate-to-severe Atopic Dermatitis With Genital Impact
NCT07444801· Source
Active, not recruiting
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with moderate to severe hidradenitis suppurativa
2025-520564-17-00· Phase 3· Source
Recruiting
A Study to Evaluate the Long-term Safety and Effectiveness of APG777 in Subjects with Atopic Dermatitis
2024-519795-11-00· Phase 2· Source
Recruiting
HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
NCT05745714· Phase 1/2· Source
Recruiting
HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
NCT05751044· Phase 1/2· Source
Recruiting
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT06926868· Phase 2/3· Source
Recruiting
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
NCT06952803· Phase 3· Source
Recruiting
Darolutamide and bipolar androgen therapy for mCRPC patients (DaroBAT)
2025-521051-23-00· Phase 2· Source
Recruiting
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
NCT06911502· Phase 3· Source
Recruiting
VyClo ITCC-092
2023-508050-26-00· Phase 1· Source
Recruiting
Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA)
NCT05690048· Phase 2· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
NCT07037901· Phase 2· Source
Recruiting
Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2
NCT07227246· Phase 3· Source
Recruiting
Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment
NCT06696183· Phase 2· Source
Active, not recruiting
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
NCT06934226· Phase 3· Source

Showing 50 of 154.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Researchers

No researcher is linked here yet.

Closed trials

Active, not recruiting
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)
NCT06726265· Phase 3· Source
Completed
A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe hidradenitis suppurativa
2024-511363-28-00· Phase 3· Source
Completed
A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
NCT06238817· Phase 3· Source
Active, not recruiting
Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma
NCT06216158· Phase 3· Source
Completed
A Study to Evaluate Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants with Relapsed or Refractory Multiple Myeloma
2023-503689-21-00· Phase 1/2· Source
Completed
A MULTICENTER OPEN LABEL 3 MONTH SAFETY STUDY WITH TRADIPITANT IN PATIENTS WITH IDIOPATHIC OR DIABETIC GASTROPARESIS
2023-503802-35-00· Phase 3· Source
Completed
A Phase 3b, Open-label Study to Evaluate the Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis
2023-505558-16-00· Phase 3· Source
Completed
A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06049017· Phase 2· Source
Completed
Magrolimab plus intensive chemotherapy in newly diagnosed “ELN intermediate or poor-risk” AML patients intended to undergo allogeneic stem cell transplantation, a Phase 2, Single-arm, Open-Label Study (MAGROLIC)
2022-502040-13-00· Phase 2· Source
Completed
Phase II, multi‑cohort trial of neoadjuvant and post‑surgery IO102‑IO103 and pembrolizumab in patients with selected resectable tumors
2022-502787-20-00· Phase 2· Source
Completed
A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis
NCT05923099· Phase 2· Source
Terminated
Holmium-166 Transarterial Radioembolization in Unresectable, Early Stage Hepatocellular Carcinoma.
NCT05451862· Source
Completed
Safety and Efficacy of Intra-arterial Tenecteplase for Noncomplete Reperfusion of Intracranial Occlusions
NCT05499832· Phase 3· Source
Completed
Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressed patients with multiple myeloma after first-line therapy (AlloRelapseMMStudy)
NCT05675319· Phase 3· Source
Completed
EFFICACY AND SAFETY TRIAL OF EPCORITAMAB WITH OR WITHOUT LENALIDOMIDE AS FIRST LINE THERAPY FOR SUBJECTS WITH DIFFUSE LARGE B-CELL LYMPHOMA.
2023-504832-16-00· Phase 2· Source
Completed
Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis
NCT05184088· Phase 3· Source
Completed
Different Doses of Naronapride vs. Placebo in Gastroparesis
NCT05621811· Phase 2· Source
Completed
PEARLDIFER - A Phase II study of pemigatinib after curative local therapy in locally advanced intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements
NCT05565794· Phase 2· Source
Completed
Symptom-based Rehabilitation Compared to Usual Care in Post-COVID - a Randomized Controlled Trial
NCT05172206· Source
Active, not recruiting
IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)
NCT05155254· Phase 3· Source
Completed
Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy
NCT05101629· Phase 2· Source
Completed
Post Market Clinical Study - Evolution® Esophageal Stent Systems, Europe: Fully and Partially Covered
NCT05182255· Source
Completed
Tiotropium in preventing preschool asthma (TIPP)
2024-513916-84-00· Phase 3· Source
Terminated
The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis
NCT04985968· Phase 3· Source
Completed
Coating to Optimize Aneurysm Treatment In The New Flow Diverter Generation
NCT04870047· Source
Completed
A Multicenter, Randomized, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn’s Disease
2024-513569-38-00· Phase 2/3· Source
Completed
Phase 3 Study of Tamibarotene Plus Azacitidine in Patients Selected for RARA-positive Higher-risk MDS (SELECT-MDS-1)
NCT04797780· Phase 3· Source
Active, not recruiting
Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab (PROTECT Extension)
NCT04598893· Phase 3· Source
Completed
Clinical Safety Study on 5-Aminolevulinic Acid (5-ALA) in Children and Adolescents With Brain Tumors
NCT04738162· Phase 2· Source
Completed
Open Label 2-Arm Study of Venetoclax in Combination with Azacitidine Versus Best Supportive Care after Allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (AML)
NCT04161885· Phase 3· Source
Completed
Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer
NCT04405349· Phase 2· Source
Completed
Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX)
NCT04330820· Phase 1/2· Source
Completed
Study on the prevention of atopic dermatitis symptoms in children with a high risk of the disease through the regular use of a moisturizing skin cream
2024-513289-21-00· Phase 3· Source
Completed
CIRCULATE
NCT04089631· Phase 3· Source
Active, not recruiting
Pediatric Long-Term Follow-up and Rollover Study
NCT03975829· Phase 4· Source
Active, not recruiting
Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)
NCT04238637· Phase 2· Source
Completed
PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial Fibrillation
NCT03996772· Phase 3· Source
Completed
EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)
NCT03594110· Phase 3· Source
Completed
A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours
NCT03468426· Phase 1· Source
Completed
MIND: Artemis in the Removal of Intracerebral Hemorrhage
NCT03342664· Source
Completed
A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma
NCT03332017· Phase 2· Source
Completed
autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized European MCL Network trial
2024-511235-10-00· Phase 3· Source
Completed
HD21
NCT02661503· Phase 3· Source
Completed
Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
NCT02283853· Phase 3· Source

Trial sites

Conditions

Diseases this institution publishes on or runs trials for.

Institution data: ROR 03b0k9c14 (CC0-1.0)Updated 12 Nov 2026

Report an error

Under construction, not live – University Hospital Augsburg: trials and research groups – Frontlight Research